Open Access

Epigallocatechin‑3‑gallate attenuates neointimal hyperplasia in a rat model of carotid artery injury by inhibition of high mobility group box 1 expression

  • Authors:
    • Bin Yang
    • Peng Gao
    • Xuejun Wu
    • Jixiang Yu
    • Yu Li
    • Ranran Meng
    • Yubin Li
    • Jingqiang Yan
    • Xing Jin
  • View Affiliations

  • Published online on: July 11, 2017     https://doi.org/10.3892/etm.2017.4774
  • Pages: 1975-1982
  • Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Epigallocatechin‑3‑gallate (EGCG) is a kind of polyphenol compound, called catechin, and is extracted from green tea. EGCG has a wide range of biological activities. The present study aimed to evaluate the effect of EGCG on neointimal hyperplasia in a rat model of carotid artery balloon injury and to explore the molecular mechanisms involved. Various experiments were performed to assess the effects of EGCG on thickening of neointima, expression levels of high mobility group box 1 protein (HMGB1) and receptor of advanced glycation end products (RAGE), the inflammatory response, oxidative stress and activation of nuclear factor (NF)‑κB. Results demonstrated that EGCG decreased the intimal area and the ratio of intimal area/medial area compared with the balloon injury group. The expression levels of HMGB1 and RAGE induced by balloon injury were markedly inhibited by EGCG treatment. Furthermore, the inflammatory response and oxidative stress damage, which have close correlations with HMGB1, were restrained by EGCG. Finally, EGCG treatment markedly inhibited NF‑κB activation. The present data provided evidence that EGCG attenuates neointimal hyperplasia in a model of carotid artery balloon injury, which indicated that EGCG may serve as a potential drug for restenosis in clinics.

Related Articles

Journal Cover

September-2017
Volume 14 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yang B, Gao P, Wu X, Yu J, Li Y, Meng R, Li Y, Yan J and Jin X: Epigallocatechin‑3‑gallate attenuates neointimal hyperplasia in a rat model of carotid artery injury by inhibition of high mobility group box 1 expression. Exp Ther Med 14: 1975-1982, 2017
APA
Yang, B., Gao, P., Wu, X., Yu, J., Li, Y., Meng, R. ... Jin, X. (2017). Epigallocatechin‑3‑gallate attenuates neointimal hyperplasia in a rat model of carotid artery injury by inhibition of high mobility group box 1 expression. Experimental and Therapeutic Medicine, 14, 1975-1982. https://doi.org/10.3892/etm.2017.4774
MLA
Yang, B., Gao, P., Wu, X., Yu, J., Li, Y., Meng, R., Li, Y., Yan, J., Jin, X."Epigallocatechin‑3‑gallate attenuates neointimal hyperplasia in a rat model of carotid artery injury by inhibition of high mobility group box 1 expression". Experimental and Therapeutic Medicine 14.3 (2017): 1975-1982.
Chicago
Yang, B., Gao, P., Wu, X., Yu, J., Li, Y., Meng, R., Li, Y., Yan, J., Jin, X."Epigallocatechin‑3‑gallate attenuates neointimal hyperplasia in a rat model of carotid artery injury by inhibition of high mobility group box 1 expression". Experimental and Therapeutic Medicine 14, no. 3 (2017): 1975-1982. https://doi.org/10.3892/etm.2017.4774